**Amendments to the Claims**

1. (currently amended) A compound of Formula (I)



(I)

or a pharmaceutically acceptable salt or solvate thereof

wherein

$A^1$ and $A^2$ are each independently $C_{1-4}$alkylene or a bond;

$A^3$ is a bond, $C_{1-4}$alkylene or $C_{1-4}$alkylidene;

$A^4$ is $C_{1-4}$alkylene or a bond and is attached to X, $X^1$ or $X^2$;

X, $X^1$, $X^2$ and $X^3$ are independently C or CH;

J is $C_{1-4}$alkyl;

p is 0 or 1;

$R^1$ and $R^2$ are independently H, $C_{1-3}$alkyl, $C_{3-6}$cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O-$C_{1-4}$alkyl or $C_{1-4}$alkyl-N(H)C(O)O-;

said $C_{3-6}$cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with $C_{1-4}$alkyl, $C_{1-3}$alkoxy, indolyl or halo;

wherein said indolyl is optionally substituted by halo or cyano;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy or cyano;

or wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form ~~pyrrolyl, pyrrolinyl,~~ pyrrolidinyl, ~~imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl,~~ piperidinyl, piperazinyl, morpholino, ~~indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl,~~ dihydroquinolinyl, tetrahydroquinolinyl, ~~isoquinolinyl,~~ dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy, cyano or benzyl;

$R^3$ is H or $C_{1-4}$alkyl;

m is 0 or 1;

$R^4$ and $R^5$ are independently hydrogen, cyano, halo, nitro, $C_{1-3}$alkyl or $C_{1-3}$perfluoroalkyl;

wherein said $R^4$ or $R^5$ may be independently attached to $G^1$, X, $X^1$, $X^2$ or $X^3$;

n is 0 or 1;

G is N, O or S;

$G^1$ is N, C or CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

both $R^4$ and $R^5$ are not attached to the same of said $G^1$, X, $X^1$, $X^2$ or $X^3$;

if G is O or S, then m is 0;

if G is N, then m is 1;

if $R_1$ is $C_{3-6}$cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with $C_{1-4}$alkyl, $C_{1-3}$alkoxy, indolyl or halo; wherein said indolyl is optionally substituted by halo or cyano, then $R_2$ is H or $C_{1-3}$alkyl;

if $R_2$ is $C_{3-6}$cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with $C_{1-4}$alkyl, $C_{1-3}$alkoxy, indolyl or halo; wherein said indolyl is optionally substituted by halo or cyano, then $R_1$ is H or $C_{1-3}$alkyl;

if $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form ~~pyrrolyl, pyrrolinyl,~~ pyrrolidinyl, ~~imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl,~~ piperidinyl, piperazinyl, morpholino, ~~indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl,~~ dihydroquinolinyl, tetrahydroquinolinyl, ~~isoquinolinyl,~~ dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy, cyano or benzyl, then p is 0;

if $R^1$ is $-N(H)C(O)OC_{1-4}$alkyl, $C_{1-4}$alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to $A^1$, then $A^1$ is $C_{2-4}$alkylene;

if $R^2$ is $-N(H)C(O)OC_{1-4}$alkyl, $C_{1-4}$alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to $A^2$, then $A^2$ is $C_{2-4}$alkylene;

if $R^1$ is $N(H)C(O)O-C_{1-4}$alkyl, $C_{1-4}$alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl,

imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy or cyano, then $R^2$ is H or $C_{1-3}$alkyl;

if $R^2$ is -N(H)C(O)O-$C_{1-4}$alkyl, $C_{1-4}$alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy or cyano, then $R^1$ is H or $C_{1-3}$alkyl;

if $R^4$ or $R^5$ are attached to $G^1$, then $G^1$ is C;

if $A^4$, $R^4$ or $R^5$ are attached to X, then X is C;

if $A^4$, $R^4$ or $R^5$ are attached to $X^1$, then $X^1$ is C;

if $A^4$, $R^4$ or $R^5$ are attached to $X^2$, then $X^2$ is C;

if $R^4$ or $R^5$ are attached to $X^3$, then $X^3$ is C.

2. (original) A compound according to claim 1 wherein p is 0.\
3. (original) A compound according to claim 1 wherein G is N and $G^1$ is CH.
4. (original) A compound according to claim 1 wherein G is S and $G^1$ is CH.
5. (original) A compound according to claim 1 wherein G is N and $G^1$ is N.
6. (original) A compound according to claim 1 wherein G is S and $G^1$ is N.
7. (original) A compound according to claim 1 wherein G is O and $G^1$ is N.
8. (original) A compound according to claim 1 wherein $R^1$ is methyl and $R^2$ is methyl.

9. (original) A compound according to claim 1 wherein $R^1$ is H and $R^2$ is $C_{3-6}$cycloalkyl wherein said $C_{3-6}$cycloalkyl is substituted with indolyl and wherein said indolyl is optionally substituted by halo or cyano.
10. (original) A compound according to claim 1 wherein $A^1$ is a bond, $R^1$ is methyl, $A^2$ is a bond and $R^2$ is methyl.
11. (original) A compound according to claim 1 wherein $R^3$ is H and m is 1.
12. (original) A compound according to claim 1 wherein $R^3$ is methyl and m is 1.
13. (original) A compound according to claim 1 wherein $R^4$ and $R^5$ are halo.
14. (original) A compound according to claim 1 wherein $R^4$ is $C_{1-3}$alkyl and is attached to $G^1$.
15. (original) A compound according to claim 1 wherein $R^4$ is $C_{1-3}$perfluoroalkyl and is attached to $G^1$.
16. (original) A compound according to claim 1 wherein $R^4$ is hydrogen.
17. (original) A compound according to claim 1 wherein $R^4$ is fluoro.
18. (original) A compound according to claim 1 wherein $R^4$ is cyano.
19. (original) A compound according to claim 1 wherein $R^4$ and $R^5$ are each fluoro.
20. (original) A compound according to claim 1 wherein the hydrogen atom attached to D is in the *trans* configuration to the hydrogen atom attached to E.
21. (original) A compound according to claim 1 wherein the hydrogen atom attached to D is in the *cis* configuration to the hydrogen atom attached to E.
22. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of S.
23. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of S; E in relation to the four moieties to which it is attached has an absolute configuration of R.
24. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of R; E in relation to the four moieties to which it is attached has an absolute configuration of S.
25. (original) A compound according to claim 1 wherein D in relation to the four moieties to which it is attached has an absolute configuration of R; E in relation to the four moieties to which it is attached has an absolute configuration of R.

26. (original) A compound according to claim 1 wherein $A^3$ is $C_{1-4}$alkylene.

27. (original) A compound according to claim 1 wherein $A^3$ is $C_{1-4}$alkylidene.

28. (original) A compound according to claim 1 wherein $A^3$ is methylene.

29. (original) A compound according to claim 1 wherein $A^3$ is a bond.

30. (original) A compound according to claim 1 wherein $A^4$ is a bond.

31. (original) A compound according to claim 1 wherein $A^4$ is methylene.

32. (original) A compound according to claim 1 wherein $A^4$ is attached $X^1$.

33. (original) A compound according to claim 1 wherein $A^4$ is attached X.

34. (original) A compound according to claim 1 wherein $R^4$ is attached X.

35. (original) A compound according to claim 1 wherein $R^4$ is attached $X^1$.

36. (original) A compound according to claim 1 wherein $R^4$ is cyano or halo and n is 0.

37. (original) A compound according to claim 1 wherein $R^1$ is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy or cyano; $A^1$ is $C_{1-4}$alkylene; $R^2$ is H or $C_{1-3}$alkylene; and $A^2$ is a bond.

38. (original) A compound according to claim 1 wherein $R^1$ is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl; $A^1$ is $C_{1-4}$alkylene; $R^2$ is H or $C_{1-3}$alkylene; and $A^2$ is a bond.

39. (original) A compound according to claim 1 wherein $R^2$ is independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy or cyano; $A^2$ is $C_{1-4}$alkylene; $R^1$ is H or $C_{1-3}$alkylene; and $A^1$ is a bond.

40. (original) A compound according to claim 1 wherein $R^2$ is independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl; $A^2$ is $C_{1-4}$alkylene; $R^1$ is H or $C_{1-3}$alkylene; and $A^1$ is a bond.
41. (original) A compound according to claim 1 wherein $R^1$ and $R^2$ are independently H, $C_{1-3}$alkyl, $C_{3-6}$cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-$C_{1-4}$alkyl.
42. (original) A compound according to claim 1 wherein $R^1$ and $R^2$ are independently H, $C_{1-3}$alkyl, or -N(H)C(O)O-$C_{1-4}$alkyl.
43. (original) A compound according to claim 1 wherein $R^1$ and $R^2$ are independently H, $C_{1-3}$alkyl, $C_{3-6}$cycloalkyl, phenyl, or -O-phenyl.
44. (original) A compound according to claim 1 wherein $R^1$ and $R^2$ are independently H, $C_{1-3}$alkyl, or are independently selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl.
45. (original) A compound according to claim 1 wherein $R^2$ is H or $C_{1-3}$alkyl and $R^1$ is $C_{3-6}$cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-$C_{1-4}$alkyl.
46. (original) A compound according to claim 1 wherein $R^2$ is H or $C_{1-3}$alkyl and $R^1$ is N(H)C(O)O-$C_{1-4}$alkyl.
47. (original) A compound according to claim 1 wherein $R^2$ is H or $C_{1-3}$alkyl and $R^1$ is $C_{3-6}$cycloalkyl, phenyl or -O-phenyl.
48. (original) A compound according to claim 1 wherein $R^2$ is H or $C_{1-3}$alkyl and $R^1$ is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl.
49. (original) A compound according to claim 1 wherein $R^1$ is H or $C_{1-3}$alkyl and $R^2$ is $C_{3-6}$cycloalkyl, phenyl, -O-phenyl, or -N(H)C(O)O-$C_{1-4}$alkyl.
50. (original) A compound according to claim 1 wherein $R^1$ is H or $C_{1-3}$alkyl and $R^2$ is N(H)C(O)O-$C_{1-4}$alkyl.
51. (original) A compound according to claim 1 wherein $R^1$ is H or $C_{1-3}$alkyl and $R^2$ is $C_{3-6}$cycloalkyl, phenyl or -O-phenyl.

52. (original) A compound according to claim 1 wherein $R^1$ is H or $C_{1-3}$alkyl and $R^2$ is selected from the group of heterocyclic moieties consisting of thienyl, imidazolyl, pyridyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, tetrahydroquinolinyl and tetrahydroisoquinolinyl.

53. (original) A compound according to claim 1 wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form pyrrolidinyl, piperidinyl, piperazinyl, morpholino, tetrahydroquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with benzyl.

54. (currently amended) A compound according to claim 1 wherein

$A^1$ and $A^2$ are each independently $C_{1-4}$alkylene or a bond;

$A^3$ is $C_{1-4}$alkylene;

$A^4$ is bond and is attached to X or $X^1$;

X and $X^1$ are each independently C or CH;

$X^2$ and $X^3$ are each CH;

p is 0;

$R^1$ and $R^2$ are independently H, $C_{1-3}$alkyl, $C_{3-6}$cycloalkyl, phenyl, -O-phenyl, -N(H)C(O)O-$C_{1-4}$alkyl or $C_{1-4}$alkyl-N(H)C(O)O-;

said $C_{3-6}$cycloalkyl, phenyl or O-phenyl being independently and optionally substituted with $C_{1-4}$alkyl, $C_{1-3}$alkoxy or halo;

or are independently selected from the group of heterocyclic moieties consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy or cyano;

or wherein $-A^1-R^1$ and $-A^2-R^2$ together with the nitrogen to which they are attached form ~~pyrrolyl, pyrrolinyl,~~ pyrrolidinyl, ~~imidazolyl,~~

~~imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl,~~ piperidinyl, piperazinyl, morpholino, ~~indolyl, isoindolyl, indolinyl, isoindolinyl, quinolinyl,~~ dihydroquinolinyl, tetrahydroquinolinyl, ~~isoquinolinyl,~~ dihydroisoquinolinyl or tetrahydroisoquinolinyl and are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy, cyano or benzyl;

$R^3$ is H or $C_{1-4}$alkyl;

m is 1;

$R^4$ is hydrogen, cyano, halo, nitro, $C_{1-3}$alkyl or $C_{1-3}$perfluoroalkyl and is attached to X or $X^1$;

n is 0;

G is N;

$G^1$ is CH;

Y is (D)H wherein D is C; and

Z is (E)H wherein E is C;

provided that

if $R^1$ is -N(H)C(O)O$C_{1-4}$alkyl, $C_{1-4}$alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to $A^1$, then $A^1$ is $C_{2-4}$alkylene;

if $R^2$ is -N(H)C(O)O$C_{1-4}$alkyl, $C_{1-4}$alkyl-N(H)C(O)O- or said heterocyclic moiety wherein said heterocyclic moiety contains a nitrogen atom and said nitrogen atom is attached to $A^2$, then $A^2$ is $C_{2-4}$alkylene;

if $R^1$ is N(H)C(O)O-$C_{1-4}$alkyl, $C_{1-4}$alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl,

tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy or cyano, then $R^2$ is H or $C_{1-3}$alkyl;

if $R^2$ is -N(H)C(O)O-$C_{1-4}$alkyl, $C_{1-4}$alkyl-N(H)C(O)O- or a heterocyclic moiety selected from the group consisting of thienyl, furanyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridyl, pyrimidinyl, piperidinyl, piperazinyl, morpholino, adamantyl, indolyl, isoindolyl, indolinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl and tetrahydroisoquinolinyl, wherein said heterocyclic moieties are optionally substituted with halo, $C_{1-4}$alkyl, $C_{1-4}$alkoxy or cyano, then $R^1$ is H or $C_{1-3}$alkyl;

if $A^4$ or $R^4$ are attached to X, then X is C;

if $A^4$ or $R^4$ are attached to $X^1$, then $X^1$ is C.

55. (original) A pharmaceutically acceptable formulation comprising a compound according to claim 1.

56. (currently amended) A method of treating depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, ~~post-traumatic stress disorder, substance abuse disorders~~ and sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.

57. (original) A method of treating sexual dysfunction comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.

58. (original) A method of treating premature ejaculation comprising the administration to a human in need thereof an effective amount of a pharmaceutically acceptable formulation comprising a compound according to claim 1.

59. (original) A compound or pharmaceutically acceptable salt or solvate thereof selected from the group consisting of

*trans*-3-(2-dimethylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;

*trans*-3-(2-methylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;

*trans*-3-(2-ethylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;

*trans*-3-(2-diethylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;

*trans*-3-{2-[(ethyl-methyl-amino)-methyl]-cyclopentyl}-1*H*-indole-5-carbonitrile;

*trans*-3-(2-pyrrolindin-1-ylmethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;

*trans*-3-{2-[(benzyl-methyl-amino)-methyl]-cyclopentyl}-1*H*-indole-5-carbonitrile;

*trans*-3-(2-dimethylaminomethyl-cyclopentyl)-1-methyl-1*H*-indole-5-carbonitrile;

*trans*-3-(2-dimethylaminomethyl-cyclopentyl)-1-ethyl-1*H*-indole-5-carbonitrile;

*trans*-5-(2-dimethylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;

*trans*-5-(2-methylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;

*trans*-5-(2-pyrrolidin-1-ylmethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;

*trans*-5-(2-ethylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;

*trans*-5-{2-[(ethyl-methyl-amino)-methyl]-cyclopentyl}-1*H*-indole-3-carbonitrile;

*trans*-5-(2-diethylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;

*trans*-5-{2-[(benzyl-methyl-amino)-methyl]-cyclopentyl}-1*H*-indole-3-carbonitrile;

*trans*-5-(2-dimethylaminomethyl-cyclopentyl)-1-methyl-1*H*-indole-3-carbonitrile;

*cis*-5-(2-methylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;

*cis*-5-(2-dimethylaminomethyl-cyclopentyl)-1*H*-indole-3-carbonitrile;

(1*R, 2R)*-3-(2-dimethylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;

*(1S, 2S)*-3-(2-dimethylaminomethyl-cyclopentyl)-1*H*-indole-5-carbonitrile;

(+) *trans*-3-[2-(1-dimethylaminoethyl)cyclopentyl]-1*H*-indole-5-carbonitrile;

(-) *trans*-3-[2-(1-dimethylaminoethyl)cyclopentyl]-1*H*-indole-5-carbonitrile;

(+) *trans*-3-[2-(1-dimethylaminopropyl)cyclopentyl]-1*H*-indole-5-carbonitrile;

(-) *trans*-3-[2-(1-dimethylaminopropyl)cyclopentyl]-1*H*-indole-5-carbonitrile;

(*1S, 2S*)-[2-(5-iodo-1*H*-indol-3-yl)-cyclopentylmethyl]-dimethylamine;

3-(2-dimethylamino-cyclopentylmethyl)-1*H*-indole-5-carbonitrile;

3-(2-methylamino-cyclopentylmethyl)-1*H*-indole-5-carbonitrile;

3-(2-ethylamino-cyclopentylmethyl)-1*H*-indole-5-carbonitrile;

3-(2-diethylamino-cyclopentylmethyl)-1*H*-indole-5-carbonitrile;

3-[2-(ethyl-methyl-amino)-cyclopentylmethyl]-1*H*-indole-5-carbonitrile;

3-(2-pyrrolidin-1-yl-cyclopentylmethyl)-1*H*-indole-5-carbonitrile; and

3-[2-(benzyl-methyl-amino)-cyclopentylmethyl]-1*H*-indole-5-carbonitrile.